Lys Therapeutics
Lyon
About Lys Therapeutics
Lys Therapeutics is a biotechnology company developing drugs to treat patients suffering from neurovascular or neurodegenerative disorders. The company's main drug is a monoclonal antibody, Glunozumab, displaying an exclusive and groundbreaking mechanism of action, that triggers off-target toxicity through hyperactivation of both vascular and neuronal NMDA receptors (NMDAr). It causes the disruption of the blood-brain and blood-spinal cord barriers and strong neuronal excitotoxicity including stroke and multiple sclerosis.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $6.3M
- Funding stage: Seed
- Last round: Non-Equity Assistance (May 2023)
- Website: lystherapeutics.com
Industries & Categories
Biotechnology, Health Care, Life Science, Medical
Social Profiles
Canonical: https://fsome.com/organization/lys-therapeutics-132610 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.